DelveInsight’s ‘ Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Progressive Supranuclear Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Progressive Supranuclear Palsy market report provides analysis regarding current treatment practices, emerging drugs like AZP2006, UCB0107, RT001 and other promising candidates like NBMIand Antisense oligonucleotide market share of the individual therapies, and historical, current and forecasted Progressive Supranuclear Palsy market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Progressive Supranuclear Palsy treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Overview:
Progressive supranuclear palsy (PSP) is an uncommon degenerative neurological disorder—the disease results from damage to nerve cells in the brain—that causes the gradual deterioration of balance and walking; speech difficulties, trouble in swallowing, diminished vision, changes in mood and behavior, and cognitive impairment. The disorder’s long name indicates that the disease worsens (progressive) and causes weakness (palsy) by damaging certain parts of the brain above nerve cell clusters called nuclei (supranuclear). These nuclei mainly control eye movements. One of the classic signs of the disease is an inability to aim and move the eyes properly, which individuals may experience as blurring of vision. While the pattern of signs and symptoms can be quite different from person to person, the most frequent first symptom of PSP is a loss of balance while walking.
It was sometimes referred to as Steele–Richardson–Olszewski syndrome, reflecting the combined names of the scientists who defined the disorder. Progressive supranuclear palsy is characterized pathologically by four-repeat (4R) Tau deposition in various cell types and anatomical regions. The broad spectrum of syndromes that have been linked to PSP pathology also includes PSP-parkinsonism, a variant that presents with features suggestive of Parkinson’s disease (PD), pure akinesia with gait freezing, corticobasal syndrome, non-fluent variant primary progressive aphasia, behavioural variant frontotemporal dementia and even PSP presenting with cerebellar ataxia.
No specific laboratory tests or imaging approaches currently exist to diagnose PSP definitively. The disease is often difficult to diagnose because its symptoms can be very much like those of other movement disorders, and because some of the most characteristic symptoms may develop late or not at all.
Progressive supranuclear palsy Treatment:
While there is currently no disease-modifying therapy for PSP, some treatment strategies have been successful for symptomatic management. The most frequently prescribed medications for symptomatic management were drugs for movement disorders, anti-infectants, and anti-depressants.
This chapter covers the details of conventional and current medical therapies available for the treatment of Progressive Supranuclear Palsy. It also provides Progressive Supranuclear Palsy treatment guidelines across the United States and Europe.
DelveInsight’s Progressive Supranuclear Palsy market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Progressive Supranuclear Palsy treatment pattern and treatment guidelines in the US and Europe.
Progressive supranuclear palsy Epidemiology:
The Progressive Supranuclear Palsy epidemiology chapters provide insights about historical and current Progressive Supranuclear Palsy patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Progressive Supranuclear Palsy epidemiology is segmented by the prevalence of PSP, phenotype associated with PSP, the gender-specific prevalence of PSP and comorbidities associated with PSP. Besides, the report includes a thorough analysis of all segments.
According to DelveInsight’s, the total prevalent population of Progressive Supranuclear Palsy in seven major markets was 82,730 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, total prevalent cases for Progressive Supranuclear Palsy were highest in Japan, followed by the United States and Germany. Spain accounted for the least number of prevalent cases among the 7MM.
Progressive supranuclear palsy Drug Chapters:
This segment encloses the detailed analysis of the drugs in the Progressive Supranuclear Palsy pipeline. It also helps understand the Progressive Supranuclear Palsy clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Treatment of PSP is symptomatic and supportive. There is no cure for the disease at the present time. Emerging therapies like AZP2006, UCB0107 and RT001 are expected to bring a positive shift to the overall market.
The market size of Progressive Supranuclear Palsy is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Progressive Supranuclear Palsy market size followed by Japan. Among the EU5 countries, the United Kingdom had the largest market size, with USD 0.70 million in 2017 while Spain had the smallest market size of PSP, with USD 0.24 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the Progressive Supranuclear Palsy market or expected to get launched in the market during the study period 2017–2030. The analysis covers Progressive Supranuclear Palsy market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of PSP market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like AZP2006, UCB0107 and RT001.
Progressive Supranuclear Palsy: Pipeline Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Pipeline Development Activities:
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Progressive Supranuclear Palsy.
To keep up with current market trends, we take KOLs and SME’s opinion working in Progressive Supranuclear Palsy domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the Progressive Supranuclear Palsy Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Which geography accounted for the largest Progressive Supranuclear Palsy market size?
The United States accounted for the largest Progressive Supranuclear Palsy market size.
What is forecasted Progressive Supranuclear Palsy size in 2030?
DelveInsight estimates an increase in Progressive Supranuclear Palsy Market Size during the study period, 2017–2030
What are the present Progressive Supranuclear Palsy market drivers?
Increasing Government Initiatives, New emerging diagnostic methods, Implementation of large Randomized Clinical Trials
What are the Progressive Supranuclear Palsy market barriers?
Poor Prognosis, Limitations in symptomatic treatment, Delayed Diagnosis, Lack of efficacious treatment, Challenges in measuring the efficacy, High costs for therapies
How many companies are developing drugs for Progressive Supranuclear Palsy?
Currently, three key pharma players are developing the drug for Progressive Supranuclear Palsy
Which are the leading companies in Progressive Supranuclear Palsy market?
Key Players – AlzProtect, UCB Biopharma, Retrotope
How is epidemiology segmented for Progressive Supranuclear Palsy?
Prevalence of PSP, phenotype associated with PSP, gender-specific prevalence of PSP and comorbidities associated with PSP
1 Key Insights
2 Executive Summary of Progressive Supranuclear Palsy
3 SWOT Analysis for Progressive Supranuclear Palsy
4 Progressive Supranuclear Palsy (PSP) Market Overview at a Glance
4.1 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2017
4.2 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2030
5 Disease Background and Overview
5.1 Introduction
5.2 Signs and symptoms
5.3 Phenotypes of Progressive Supranuclear Palsy
5.4 History
5.5 Associated risk factors
5.6 Genetics
5.7 Pathophysiology
5.8 PSP associated abnormalities
5.9 Clinical Presentation and Assessment
5.10 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria
5.11 PET Imaging as a Biomarker in Tauopathies
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]
7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.2 Total Prevalent Patient Population of PSP in the United States
7.1.3 Phenotype associated with PSP in the United States
7.1.4 Gender specific Prevalence of PSP in the United States
7.1.5 Comorbidities associated with PSP in the United States
7.2 EU5 Countries
7.2.1 Assumptions and Rationale
7.2.2 Germany
7.2.2.1 Total Prevalent Patient Population of PSP in Germany
7.2.2.2 Phenotype associated with PSP in Germany
7.2.2.3 Gender specific Prevalence of PSP in Germany
7.2.2.4 Comorbidities associated with PSP in Germany
7.2.3 France
7.2.3.1 Total Prevalent Patient Population of PSP in France
7.2.3.2 Phenotype associated with PSP in France
7.2.3.3 Gender specific Prevalence of PSP in France
7.2.3.4 Comorbidities associated with PSP in France
7.2.4 Italy
7.2.4.1 Total Prevalent Patient Population of PSP in Italy
7.2.4.2 Phenotype associated with PSP in Italy
7.2.4.3 Gender specific Prevalence of PSP in Italy
7.2.4.4 Comorbidities associated with PSP in Italy
7.2.5 Spain
7.2.5.1 Total Prevalent Patient Population of PSP in Spain
7.2.5.2 Phenotype associated with PSP in Spain
7.2.5.3 Gender specific Prevalence of PSP in Spain
7.2.5.4 Comorbidities associated with PSP in Spain
7.2.6 The United Kingdom
7.2.6.1 Total Prevalent Patient Population of PSP in the United Kingdom
7.2.6.2 Phenotype associated with PSP in the United Kingdom
7.2.6.3 Gender specific Prevalence of PSP in the United Kingdom
7.2.6.4 Comorbidities associated with PSP in the United Kingdom
7.3 Japan
7.3.1 Assumptions and Rationale
7.3.2 Total Prevalent Patient Population of PSP in Japan
7.3.3 Phenotype associated with PSP in Japan
7.3.4 Gender specific Prevalence of PSP in Japan
7.3.5 Comorbidities associated with PSP in Japan
8 Treatment
8.1 Current symptomatic treatment
9 Unmet Needs
10 Emerging drugs
10.1 AZP2006: Alzprotect
10.1.1 Product Description
10.1.2 Other Development Activities
10.1.3 Clinical Development
10.1.3.1 Clinical Trials Information
10.1.4 Safety and efficacy
10.2 UCB0107: UCB Biopharma
10.2.1 Product Description
10.2.2 Product Development Activity
10.2.3 Clinical Development
10.2.3.1 Clinical Trials Information
10.2.4 Safety and efficacy
10.3 RT001: Retrotope
10.3.1 Product Description
10.3.2 Other Development Activities
10.3.3 Safety and efficacy
11 Other promising candidates
11.1 NBMI: EmeraMed
11.1.1 Product Description
11.1.2 Clinical Development
11.2 Antisense oligonucleotide: Novartis
11.2.1 Product Description
11.2.2 Clinical Development
11.2.2.1 Clinical trials information
12 No development reported
12.1 ASN 120290: Asceneuron
12.1.1 Product Description
12.1.2 Other Development Activities
12.1.3 Clinical Development
12.1.4 Safety and efficacy
13 Discontinued therapies
13.1 ABBV-8E12: AbbVie
13.1.1 Product Description
13.2 Gosuranemab: Biogen
13.2.1 Product Description
14 Progressive Supranuclear Palsy (PSP): Seven Major Market Analysis
14.1 Key Findings
14.2 Total Market Size of PSP in 7MM
14.3 Market Outlook: 7MM
15 United States
15.1 Total Market size of PSP
15.2 PSP Market Size by Therapies
16 EU5 Countries
16.1 Germany
16.1.1 Total Market size of PSP
16.1.2 PSP Market Size by Therapies
16.2 France
16.2.1 Total Market size of PSP
16.2.2 PSP Market Size by Therapies
16.3 Italy
16.3.1 Total Market size of PSP
16.3.2 PSP Market Size by Therapies
16.4 Spain
16.4.1 Total Market size of PSP
16.4.2 PSP Market Size by Therapies
16.5 United Kingdom
16.5.1 Total Market size of PSP
16.5.2 PSP Market Size by Therapies
17 Japan
17.1 Total Market size of PSP
17.2 PSP Market Size by Therapies
18 Market Drivers
19 Market Barriers
20 Appendix
20.1 Bibliography
20.2 Report Methodology
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight
List of Table
Table 1: Summary of Progressive Supranuclear Palsy (PSP) Market, Epidemiology, and Key Events (2017–2030)
Table 2: Core clinical features
Table 3: Supportive Features
Table 4: Diagnostic criteria for PSP
Table 5: Total Prevalent Patient Population of PSP in 7MM (2017–2030)
Table 6: Total Prevalent Population of PSP in the United States (2017–2030)
Table 7: Phenotype associated with PSP in the United States (2017–2030)
Table 8: Gender-specific Prevalence of PSP in the United States (2017–2030)
Table 9: Comorbidities associated with PSP in the United States (2017–2030)
Table 10: Total Prevalent Population of PSP in Germany (2017–2030)
Table 11: Phenotype associated with PSP in Germany (2017–2030)
Table 12: Gender-specific Prevalence of PSP in Germany (2017–2030)
Table 13: Comorbidities associated with PSP in Germany (2017–2030)
Table 14: Total Prevalent Population of PSP in France (2017–2030)
Table 15: Phenotype associated with PSP in France (2017–2030)
Table 16: Gender-specific Prevalence of PSP in France (2017–2030)
Table 17: Comorbidities associated with PSP in France (2017–2030)
Table 18: Total Prevalent Population of PSP in Italy (2017–2030)
Table 19: Phenotype associated with PSP in Italy (2017–2030)
Table 20: Gender-specific Prevalence of PSP in Italy (2017–2030)
Table 21: Comorbidities associated with PSP in Italy (2017–2030)
Table 22: Total Prevalent Population of PSP in Spain (2017–2030)
Table 23: Phenotype associated with PSP in Spain (2017–2030)
Table 24: Gender-specific Prevalence of PSP in Spain (2017–2030)
Table 25: Comorbidities associated with PSP in Spain (2017–2030)
Table 26: Total Prevalent Population of PSP in the United Kingdom (2017–2030)
Table 27: Phenotype associated with PSP in the United Kingdom (2017–2030)
Table 28: Gender-specific Prevalence of PSP in the United Kingdom (2017–2030)
Table 29: Comorbidities associated with PSP in the United Kingdom (2017–2030)
Table 30: Total Prevalent Population of PSP in Japan (2017–2030)
Table 31: Phenotype associated with PSP in Japan (2017–2030)
Table 32: Gender-specific Prevalence of PSP in Japan (2017–2030)
Table 33: Comorbidities associated with PSP in Japan (2017–2030)
Table 34: AZP2006, Clinical Trial Description, 2020
Table 35: UCB0107, Clinical Trial Description, 2020
Table 33: Antisense oligonucleotide, Clinical Trial Description, 2020
Table 36: Seven Major Market Size of PSP in USD Million (2017–2030)
Table 37: The US Market size of PSP in USD Million (2017–2030)
Table 38: The US market size of PSP by Therapies in USD Million (2017–2030)
Table 39: Germany Market size of PSP in USD Million (2017–2030)
Table 40: Germany market size of PSP by Therapies in USD Million (2017–2030)
Table 41: France Market size of PSP in USD Million (2017–2030)
Table 42: France market size of PSP by Therapies in USD Million (2017–2030)
Table 43: Italy Market size of PSP in USD Million (2017–2030)
Table 44: Italy market size of PSP by Therapies in USD Million (2017–2030)
Table 45: Spain Market size of PSP in USD Million (2017–2030)
Table 46: Spain market size of PSP by Therapies in USD Million (2017–2030)
Table 47: The UK Market size of PSP in USD Million (2017–2030)
Table 48: The UK market size of PSP by Therapies in USD Million (2017–2030)
Table 49: Japan Market size of PSP in USD Million (2017–2030)
Table 50: Japan market size of PSP by Therapies in USD Million (2017–2030)
List of Figures
Figure 1: SWOT Analysis
Figure 2: Tau isoforms and conformations
Figure 3: Tau hyperphosphorylation and aggregation
Figure 4: Total Prevalent Patient Population of PSP in 7MM (2017–2030)
Figure 5: Prevalence of PSP in the United States (2017–2030)
Figure 6: Phenotype associated with PSP in the United States (2017–2030)
Figure 7: Gender-specific Prevalence of PSP in the United States (2017–2030)
Figure 8: Comorbidities associated with PSP in the United States (2017–2030)
Figure 9: Prevalence of PSP in Germany (2017–2030)
Figure 10: Phenotype associated with PSP in Germany (2017–2030)
Figure 11: Gender-specific Prevalence of PSP in Germany (2017–2030)
Figure 12: Comorbidities associated with PSP in Germany (2017–2030)
Figure 13: Prevalence of PSP in France (2017–2030)
Figure 14: Phenotype associated with PSP in France (2017–2030)
Figure 15: Gender-specific Prevalence of PSP in France (2017–2030)
Figure 16: Comorbidities associated with PSP in France (2017–2030)
Figure 17: Prevalence of PSP in Italy (2017–2030)
Figure 18: Phenotype associated with PSP in Italy (2017–2030)
Figure 19: Gender-specific Prevalence of PSP in Italy (2017–2030)
Figure 20: Comorbidities associated with PSP in Italy (2017–2030)
Figure 21: Prevalence of PSP in Spain (2017–2030)
Figure 22: Phenotype associated with PSP in Spain (2017–2030)
Figure 23: Gender-specific Prevalence of PSP in Spain (2017–2030)
Figure 24: Comorbidities associated with PSP in Spain (2017–2030)
Figure 25: Prevalence of PSP in the United Kingdom (2017–2030)
Figure 26: Phenotype associated with PSP in the United Kingdom (2017–2030)
Figure 27: Gender-specific Prevalence of PSP in the United Kingdom (2017–2030)
Figure 28: Comorbidities associated with PSP in the United Kingdom (2017–2030)
Figure 29: Prevalence of PSP in Japan (2017–2030)
Figure 30: Phenotype associated with PSP in Japan (2017–2030)
Figure 31: Gender-specific Prevalence of PSP in Japan (2017–2030)
Figure 32: Comorbidities associated with PSP in Japan (2017–2030)
Figure 33: Potential therapeutic targets for progressive supranuclear palsy
Figure 34: Potential therapeutic targets for progressive supranuclear palsy
Figure 35: Unmet Needs of PSP
Figure 36: Seven Major Market Size of PSP in USD Million (2017–2030)
Figure 37: Market Size of PSP in the United States, USD Millions (2017–2030)
Figure 38: The US market size of PSP by therapies in USD Million (2017–2030)
Figure 39: Market Size of PSP in Germany, USD Millions (2017–2030)
Figure 40: Germany market size of PSP by therapies in USD Million (2017–2030)
Figure 41: Market Size of PSP in France, USD Millions (2017–2030)
Figure 42: France market size of PSP by therapies in USD Million (2017–2030)
Figure 43: Market Size of PSP in Italy, USD Millions (2017–2030)
Figure 44: Italy market size of PSP by therapies in USD Million (2017–2030)
Figure 45: Market Size of PSP in Spain, USD Millions (2017–2030)
Figure 46: Spain market size of PSP by therapies in USD Million (2017–2030)
Figure 47: Market Size of PSP in the UK, USD Millions (2017–2030)
Figure 48: The UK market size of PSP by therapies in USD Million (2017–2030)
Figure 49: Market Size of PSP in Japan, USD Millions (2017–2030)
Figure 50: Japan market size of PSP by therapies in USD Million (2017–2030)
Figure 51: Market Drivers
Figure 52: Market Barriers
